The group of Zonghai LI at Renji Hospital’s Shanghai Cancer Research Institute and Keji Biomedical (Shanghai) Co. have jointly developed more than ten candidate CAR-T products (chimeric antigen-modified T lymphocytes”), covering leukemia, lymphoma, myeloma, liver cancer, lung cancer, gastric cancer, pancreatic cancer, brain glioblastoma, esophageal cancer and other human cancers. By the end of 2018, the team plans for at least 5 CFDA new drug clinical research approvals and 1 or 2 US FDA clinical research approvals. They plan to have the first CAR-T products registered in 2020.”
China Bio news release, May 2, 2017